Aller au contenu
Nutrition et métabolismeEssai randomisé4 min read

Added to insulin, a three-strain probiotic was linked to better glucose control in type 1 diabetes

Collectif éditorial MoveVitals · Study published · Reading updated

Original paper:Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus. · Frontiers in endocrinology · 2022 · Article original ↗

À retenir

In a double-blind trial of patients aged 6 to 18 with type 1 diabetes, 6 months of a three-strain probiotic added to insulin lowered fasting glucose and HbA1c versus before treatment and reduced several inflammatory markers. With only 27 patients on probiotics and the abstract giving no numerical effect sizes, it is an early signal rather than proof of benefit.

Study design

Essai randomisé

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.

Question de recherche

Type 1 diabetes (T1DM) arises when the immune system destroys the pancreas's insulin-making beta cells, and gut bacteria help regulate immunity. The authors tested whether adding specific probiotic strains to regular insulin could improve blood sugar control (HbA1c) and inflammatory markers, and how the probiotics changed gut bacteria.

Population et méthode

Randomized, double-blind, placebo-controlled trial at China Medical University Hospital (ClinicalTrials.gov NCT03880760) in T1DM patients aged 6 to 18. 27 patients took regular insulin plus daily capsules of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68 and Bifidobacterium animalis subsp. lactis CP-9 for 6 months, and 29 took insulin without extra probiotics as the placebo group. Fasting blood glucose and HbA1c were tracked, inflammatory and anti-inflammatory cytokines were measured with enzyme-linked immunosorbent assay, and stool microbiota was analyzed by next-generation sequencing (NGS).

Résultats

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Gut sequencing showed higher populations of Bifidobacterium animalis, Akkermansia muciniphila and Lactobacillus salivarius in patients taking probiotics.
  2. 2
    Fasting blood glucose was significantly lower after the probiotic than before the intervention, and HbA1c also improved after the probiotic. The abstract does not give the amounts or a direct comparison with the placebo group for these.
  3. 3
    Concentrations of IL-8, IL-17, MIP-1β, RANTES and TNF-α fell significantly, alongside increased TGF-β1 expression, after the probiotic.
  4. 4
    The improvements in glycemic control and immune markers were still seen 3 months after the probiotics were stopped.

Limites et incertitude

  1. 1
    Small trial (27 probiotic, 29 placebo) at one hospital, in children and adolescents only.
  2. 2
    The glucose result is described as a before-versus-after change, and the abstract gives no numbers, so it is unclear how much of the change exceeds the placebo group's.
  3. 3
    The probiotic combination had three specific strains, so results do not apply to other probiotic products.
  4. 4
    Blood sugar and cytokine changes do not show long-term outcomes such as complications or hypoglycemia. This reading is based on the abstract only.

Mise en perspective

This early trial suggests a specific probiotic mix, taken alongside insulin, may improve markers of blood sugar and inflammation in young people with type 1 diabetes. It does not mean probiotics can replace or reduce insulin, and results from three named strains cannot be assumed for products on a shelf. Any change to diabetes care should be discussed with the diabetes team.

Vos données

For someone with type 1 diabetes, continuous glucose monitor (CGM) time in range and HbA1c are the numbers to follow with their care team. Compare similar weeks with the same sensor, and do not stop or change insulin because of a supplement.

Comprendre ce type de preuve

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Résumé structuré des auteurs English

Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.

Introduction

Type 1 diabetes mellitus (T1DM) is characterized by autoimmune destruction of pancreatic β cells. Previous study has discovered that probiotic strains residing in the gut play essential roles in host immune regulation. However, few clinical results demonstrated probiotic would actually benefit in attenuating glycated hemoglobin (HbA1c) along with inflammatory cytokine levels of the T1DM patients and analyzed their gut microbiota profile at the same time. In this clinical trial, we evaluated the therapeutic efficacy of probiotics on HbA1c along with inflammatory cytokine levels of T1DM patients to determine an alternative administration mode for T1DM medication. The probiotics changed T1DM gut microbiota profile will be measured by next-generation sequencing (NGS).

Research design and methods

A randomized, double-blind, placebo-controlled trial was performed at China Medical University Hospital. T1DM patients between 6 and 18 years of age were enrolled. 27 patients were administered regular insulin therapy plus capsules containing probiotic strains Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 daily for 6 months, and 29 patients were administered insulin therapy without extra probiotic supplement as placebo group. The variations of fasting blood glucose and HbA1c in these patients were analyzed. In addition, serum levels of inflammatory cytokines and anti-inflammatory cytokine were assessed using enzyme-linked immunosorbent assay. Patients' stool microbiota were all subjects to NGS analysis.

Results

NGS data showed elevated populations of Bifidobacterium animalis, Akkermansia muciniphila and Lactobacillus salivarius in the gut of patients with T1DM who were taking probiotics. Patients with T1DM who were administered probiotics showed significantly reduced fasting blood glucose levels compared with the before-intervention levels. The HbA1c levels of the patients also improved after administration of probiotics. The concentrations of IL-8, IL-17, MIP-1β, RANTES, and TNF-α were significantly reduced and were associated with an increased TGF-β1 expression after probiotic intervention. The persistence effect of glycemic control and immunomodulation were observed even 3 months after discontinuation of the probiotics.

Conclusions

Here, we found that conventional insulin therapy plus probiotics supplementation attenuated T1DM symptoms than receiving insulin treatment only. Probiotics supplementation with insulin treatment changed gut microbiota and revealed better outcome in stabilizing glycemic levels and reducing HbA1c levels in patients with T1DM through beneficial regulation of immune cytokines.

Clinical trial registration

ClinicalTrials.gov, identifier NCT03880760.

Sources et attribution

Adjuvant Probiotics of Lactobacillus salivarius subsp. salicinius AP-32, L. johnsonii MH-68, and Bifidobacterium animalis subsp. lactis CP-9 Attenuate Glycemic Levels and Inflammatory Cytokines in Patients With Type 1 Diabetes Mellitus.

Wang CH, Yen HR, Lu WL, Ho HH, Lin WY, Kuo YW, Huang YY, Tsai SY, Lin HC.

Frontiers in endocrinology · 2022-03-01

DOI: 10.3389/fendo.2022.754401 ↗PubMed · 35299968 ↗Europe PMC · Licence indiquée: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée

Sources vérifiées 2026-11-01

Guides pratiques

À lire ensemble

·Méta-analyse d’essais

Early time-restricted eating linked to more weight loss and lower insulin than late eating

Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.

BMJ Medicine

Explications approfondiesLire l’étude →
·Essai randomisé

An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss

Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
·Essai randomisé

In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain

In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.

Cell Metabolism

Explications approfondiesLire l’étude →
·Essai randomisé

Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)

Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.

The New England Journal of Medicine

Explications approfondiesLire l’étude →
Nutrition et métabolisme →